APOE effects on regional tau in preclinical Alzheimer's disease.

"table 1 demographic information for the a4/learn dataset full dataset"

"Declarations Ethics approval and consent to participateAll A4 participants completed written informed consent before participation. All ADNI participants provided written informed consent in compliance with local IRBs. Consent for publicationNot applicable. Competing interestsKLP received consulting fees from CuraSen Therapeutics Inc. ECM is a paid consultant for Roche, Genentech, and Eli Lilly. All other authors have no disclosures relevant to the manuscript. Competing interests KLP received consulting fees from CuraSen Therapeutics Inc. ECM is a paid consultant for Roche, Genentech, and Eli Lilly. All other authors have no disclosures relevant to the manuscript."

"Funding This study was supported by grants K99AG071837 (CBY), K99AG075238 (MEB), U24AG074855 (ECM), P30AG066515 (ECM, KLP, MEB), R01NS115114 (KLP, ECM), K01AG051718 (ECM), P01AG036694 (RAS, KAJ), and P50AG005134 (RAS) from the National Institute of Health; and AARFD-21-849349 (CBY) and AARF-20-683984 (MEB) from the Alzheimer’s Association."